DeepMed Research

Georgetown University

🇬🇹Guatemala

Country: 🇬🇹Guatemala

Ownership: Private

Established: 1789-01-23

Employees: 5K

Market Cap: -

Website: http://www.georgetown.edu

Clinical Trials

The Effects of Opioid Taper on Opioid-Induced Hyperalgesia

Terminated

Conditions: Buprenorphine
Pain

Interventions: Drug: Buprenorphine

First Posted Date: 2017-02-24

Last Posted Date: 2018-03-21

Lead Sponsor: Georgetown University

Target Recruit Count: 15

Registration Number: NCT03063905

Locations: 🇺🇸
Avery Road Treatment Center, Rockville, Maryland, United States
🇺🇸
Kolmac Clinic, Silver Spring, Maryland, United States

Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis

Completed

Conditions: Streptococcal Infections

Interventions: Diagnostic Test: Rapid strep antigen detection test
Diagnostic Test: throat culture

First Posted Date: 2017-02-16

Last Posted Date: 2018-06-07

Lead Sponsor: Georgetown University

Target Recruit Count: 600

Registration Number: NCT03055728

Locations: 🇺🇸
Northern Virginia Pediatrics, Falls Church, Virginia, United States

ENGAGED 2 Study: Experiences With Mammography Screening and Breast Density 2

Not Applicable

Completed

Conditions: Breast Cancer Female
Breast Density

Interventions: Behavioral: Usual Care Arm
Behavioral: Personalized Web Intervention Arm

First Posted Date: 2017-01-24

Last Posted Date: 2025-04-30

Lead Sponsor: Georgetown University

Target Recruit Count: 995

Registration Number: NCT03029286

Locations: 🇺🇸
Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States

Predictors of Adjuvant Endocrine Therapy in Women With Breast Cancer

Conditions: Breast Cancer Female

Interventions: Behavioral: No Intervention

First Posted Date: 2016-12-14

Last Posted Date: 2019-06-07

Lead Sponsor: Georgetown University

Target Recruit Count: 630

Registration Number: NCT02992730

Locations: 🇺🇸
Georgetown University, Washington, District of Columbia, United States

LEE011 Plus Everolimus in Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy

Phase 1

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: LEE011
Drug: Everolimus

First Posted Date: 2016-12-07

Last Posted Date: 2019-05-21

Lead Sponsor: Georgetown University

Target Recruit Count: 44

Registration Number: NCT02985125

Locations: 🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Phase 2

Terminated

Conditions: Acral Lentiginous Melanoma
Mucosal Melanoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2016-12-01

Last Posted Date: 2024-04-04

Lead Sponsor: Georgetown University

Target Recruit Count: 14

Registration Number: NCT02978443

Locations: 🇺🇸
Washington Cancer Institute at MedStar Washington Hospital Center, Washington, District of Columbia, United States
🇺🇸
John Theurer Cacner Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

and more 2 locations

Molecularly Tailored Therapy to Standard of Care as Second-Line Therapy in Metastatic Pancreatic Cancer

Phase 2

Withdrawn

Conditions: Metastatic Pancreatic Cancer

Interventions: Other: Molecularly Tailored Second Line Therapy
Drug: Standard of Care Second Line Therapy

First Posted Date: 2016-11-18

Last Posted Date: 2018-09-11

Lead Sponsor: Georgetown University

Registration Number: NCT02967770

Locations: 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

The Genetic Education for Men Trial: Web-Based Education vs. Standard Care

Not Applicable

Completed

Conditions: BRCA2 Mutation
BRCA1 Mutation
Prostate Carcinoma
Breast Neoplasm
Pancreatic Cancer

Interventions: Behavioral: Web-based Counseling
Behavioral: Standard Care

First Posted Date: 2016-11-08

Last Posted Date: 2023-09-13

Lead Sponsor: Georgetown University

Target Recruit Count: 63

Registration Number: NCT02957981

Locations: 🇺🇸
Georgetown University Medical Center/Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma

Phase 1

Active, not recruiting

Conditions: Refractory Follicular Lymphoma
Relapsed Follicular Lymphoma

Interventions: Drug: Ibrutinib
Drug: Venetoclax

First Posted Date: 2016-11-06

Last Posted Date: 2024-05-21

Lead Sponsor: Georgetown University

Target Recruit Count: 24

Registration Number: NCT02956382

Locations: 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

Impact of Nilotinib on Safety, Tolerability, Pharmacokinetics and Biomarkers in Parkinson's Disease

Phase 2

Conditions: Parkinson Disease
Parkinsons Disease With Dementia

Interventions: Drug: Nilotinib 300mg oral capsule [Tasigna]
Drug: Placebo Oral Capsule
Drug: Nilotinib 150mg oral capsule [Tasigna]

First Posted Date: 2016-11-04

Last Posted Date: 2019-03-14

Lead Sponsor: Georgetown University

Target Recruit Count: 75

Registration Number: NCT02954978

Locations: 🇺🇸
MedStar Georgetown University Hospital, Washington, District of Columbia, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy